Avalon Ventures XI, L.P.

All filings by Avalon Ventures XI, L.P. on record concern Janux Therapeutics, Inc. Over a trading history stretching from 15 June 2021 to 16 October 2024, the count stands at 15 filings.

In open-market terms, that means 1 purchase worth €4.7M on one side and 8 sales worth €48.5M on the other. The net balance comes to €43.8M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 4 option exercises. So far in 2024, the count stands at no purchases and 8 sales.

The latest filing, published on 18 October 2024, reports an open-market sale of €2.8M in Janux Therapeutics, Inc. The last purchase on record was published on 13 November 2023, which is 1,070 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.